New drug for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new oral medication called AQUA07 for people with a specific type of lung cancer (ALK-positive non-small cell lung cancer) that has grown or spread despite prior treatment with certain targeted drugs (ALK inhibitors). It aims to see if this new drug can control the cancer and be safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (or 20 in some countries).
- You must have ALK-positive non-small cell lung cancer that is advanced or has spread, and it must have worsened or caused unacceptable side effects with your most recent treatment.
- You must have already been treated with at least one ALK inhibitor (like alectinib, brigatinib, or lorlatinib), but not crizotinib alone.
- You must have tumors that can be measured on scans (RECIST criteria).
- You must be able to take oral medications and have adequate organ function.
- Your cancer must not have uncontrolled symptoms in the brain (treated stable brain metastases are okay). You should not have serious heart, lung, or other disease, or a history of interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.